WS #10275
AbbVie reportedly in talks to buy a biotech for $10.9B for an experimental eczema drug, potentially boosting ABBV and the target.
AbbVie biotech acquisition target
AbbVie reportedly in talks to buy a biotech for $10.9B for an experimental eczema drug, potentially boosting ABBV and the target.